权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Regulation of xenobiotic receptors PXR and CAR: implications in drug disposition

外源性受体 PXR 和 CAR 的调节：对药物处置的影响

基本信息

批准号：
9889965
负责人：
Taosheng Chen
金额：
$ 30.01万
依托单位：
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-04-01 至 2021-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9889965
关键词：
Affect Agonist Binding Biological Availability Cell physiology Cells Chemicals Comprehension Crystallization DNA Development Diabetes Mellitus Drug Sensitization Drug resistance Drug toxicity Elements Enzymes Funding Genes Genetic Transcription Genotoxic Stress Goals Homeostasis Human Human body Malignant Neoplasms MicroRNAs Nuclear Receptors Pathway interactions Pharmaceutical Preparations Post-Transcriptional Regulation Post-Translational Protein Processing Proteins RXR Regulation Role Signal Transduction Signaling Molecule Structure Therapeutic Toxic effect Treatment Efficacy Treatment Failure Xenobiotics analog chemotherapeutic agent constitutive androstane receptor drug disposition drug metabolism genetic corepressor genotoxicity human disease improved novel pregnane X receptor prevent promoter protein protein interaction public health relevance receptor receptor binding response tool

项目摘要

DESCRIPTION (provided by applicant): We study regulation of the human pregnane X receptor (hPXR) and constitutive androstane receptor (hCAR) and their roles in drug disposition. Both hPXR and hCAR: 1) are nuclear receptors modulated by many structurally diverse chemicals, either directly via receptor binding or indirectly via signaling cross-talk; 2) transcriptionally regulate drug metabolizing enzymes and transporters to control xenobiotic disposition and endobiotic homeostasis; 3) are implicated not only in drug effects but also in the development of human diseases, such as diabetes and cancer; 4)form heterodimers with retinoid X receptor to bind the promoters of their target genes, which may be unique to a receptor or overlap; 5) are affected by coactivators and corepressors; and 6) interact similarly or differently with various regulatory partners, including chemicals, DNA elements, proteins, and microRNAs. Several key gaps remain in our overall understanding of hPXR and hCAR regulation and function. First, hPXR and hCAR not only regulate drug metabolism but also interact with other signaling molecules, regulating or being regulated by them. Despite ongoing progress, we lack a complete picture of hPXR and hCAR interactions with their regulators, and of the regulation by and regulation of these interactions. Second, a systematic effort is needed to develop chemical tools to dissect hPXR and hCAR regulation in detail. Our two long-term goals are to comprehensively examine the regulation of hPXR and hCAR and its implications for drug disposition and human diseases, and to develop chemical tools to elucidate hPXR and hCAR regulation and its potential application for preventing drug toxicity and improving bioavailability. We have advanced toward these goals by discovering mechanisms that regulate hPXR and hCAR, including protein-protein interactions, post-translational modification and post-transcriptional regulation (microRNAs), and by developing the novel hPXR antagonist SPA70, the hCAR inverse agonist CINPA1, and their analogs. We will meet 3 challenges during the funding period: (1) Illustrate how hPXR and hCAR regulate drug toxicity and resistance by examining to what extent SPA70 prevents drug toxicity and CINPA1 reduces drug resistance and determining the underlying mechanisms. (2) Define the fundamental mechanism responsible for the action of hPXR antagonists and hCAR inverse agonists by obtaining the co-crystal structures of hPXR with antagonist (SPA70) and hCAR with inverse agonist (CINPA1) and carrying out structural-functional analysis. (3) Better understand hPXR and hCAR protein-protein interaction networks and reciprocal regulatory effects, starting by examining how signaling cross-talk between genotoxic- and xenobiotic-responsive pathways reduces the effect of genotoxic stress. Together, our findings will provide not only a broader comprehension of the regulation of hPXR and hCAR and how they control the human body's response to xenobiotic s and endobiotics, but also novel modulators of hPXR and hCAR for further interrogating their broad cellular function, and as leads for therapies to prevent drug toxicity and improve drug bioavailability.